A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Survodutide identity.
Crossref dates: December 17, 2025 and February 1, 2026. Checked August 19, 2026. The metadata identifies a connected notice but does not describe its scientific impact.
ClinicalTrials.gov posted a newer version of NCT06077864, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-08-13T05:52:27.018Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was survodutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide.
1. PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-08-13T05:52:27.018Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct06077864-2026-08-11-60e24ca2b385]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06077864-2026-08-11-60e24ca2b385]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct06077864-2026-08-11-60e24ca2b385-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06077864-2026-08-11-60e24ca2b385-r2]
ClinicalTrials.gov posted a newer version of NCT06632457, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-08-13T05:52:27.009Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide.
1. PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-08-13T05:52:27.009Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad-r2]
ClinicalTrials.gov posted a newer version of NCT07754461, with a registry update date of 2026-11-13. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 13, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was survodutide.
1. PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct07754461-2026-08-10-d71d6065261a]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07754461-2026-08-10-d71d6065261a]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct07754461-2026-08-10-d71d6065261a-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07754461-2026-08-10-d71d6065261a-r2]
We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which names survodutide among unapproved drugs sold with false research-use labels.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
Investigational
After
In clinical trials; not FDA-approved
Profile summary
Before
A glucagon/GLP-1 receptor agonist candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.
After
An experimental glucagon and GLP-1 receptor dual agonist from Boehringer Ingelheim, studied in obesity and fatty liver disease. It is not FDA-approved.
Evidence note
Before
ClinicalTrials.gov lists a Boehringer Ingelheim study as active, not recruiting, updated July 22, 2026.
After
Published randomized trials, including the Phase 3 SYNCHRONIZE-1 trial, report weight loss and liver-fat reductions. A completed cardiovascular safety trial has no results in the cited sources. FDA has warned companies selling unapproved survodutide with false research-use labels.
Showing the latest 18 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 16, 2026.
PeptideScanner retained ClinicalTrials.gov record NCT07940244 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT07221591 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT07768813 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT07850050 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT07850063 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT07855900 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was survodutide.
PubMed lists PMID 42897119 in Diabetes, obesity & metabolism as Letter, with publication-date metadata of 2026-10-19 (day precision). PeptideScanner associated the retained record with the identity slug survodutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT07413913 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-15, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-08-13T05:52:27.018Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT06632444 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-08-13T05:52:27.009Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained PubMed bibliographic metadata for PMID 40557206 at 2026-07-30T18:26:54.791Z. PubMed recorded a metadata revision date of 2025-06-25 and an Entrez history date of 2025-06-25. PeptideScanner associated this retained record with the identity slug survodutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 41388343 at 2026-07-30T16:25:14.127Z. PubMed recorded a metadata revision date of 2026-02-14 and an Entrez history date of 2025-12-13. PeptideScanner associated this retained record with the identity slug survodutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 41424209 at 2026-07-30T16:25:14.150Z. PubMed recorded a metadata revision date of 2026-02-10 and an Entrez history date of 2025-12-22. PeptideScanner associated this retained record with the identity slug survodutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT06176365 at 2026-07-30T16:20:49.317Z. Its registry update date was 2026-04-30, and PeptideScanner's reviewed identity mapping was survodutide.
PeptideScanner retained ClinicalTrials.gov record NCT06309992 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-30, and PeptideScanner's reviewed identity mapping was survodutide.